

A study to examine the performance and safety of the Eagle device by collecting data from patients being treated for glaucoma or ocular hypertension with the Eagle device

Submission date 28/03/2024	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 02/07/2024	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 27/05/2026	Condition category Eye Diseases	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

This study is designed to evaluate the performance and safety of the Eagle® device when used within the intended use covered by the CE marking and following the Standard of Care. The Eagle device is a laser device for direct selective laser trabeculoplasty (DSLTL) for the treatment of glaucoma. The laser treatment with the Eagle device is performed without the need to use a lens that touches the eye as in the traditional laser treatment. An image processing algorithm automatically localises the target area, which the operator or eye care professional (ECP) readjusts if necessary. Once the operator has confirmed the target area, an eye-tracking system enables the eye movement to be tracked so that the laser pulses are delivered precisely to the target area.

Who can participate?

Patients aged 18 years old and over who underwent treatment with the eagle device for treatment of open-angle glaucoma including exfoliative or pigmentary glaucoma or ocular hypertension as per the approved indication with expected post-operative follow-up data of at least six months

What does the study involve?

This study is a registry designed to evaluate the performance and safety of the Eagle® device when used within the intended use covered by the CE marking and following the Standard of Care. The study will register the information usually collected by your doctor at the time points specified by them. The only requirement is that two doctor visits be recorded so the performance and safety of the treatment with the Eagle device can be evaluated.

What are the possible benefits and risks of participating?

Participants are unlikely to derive any personal health benefits from participating in this study

because the collection of data for the registry is independent of the standard of care decisions made by their doctor. However, the results of the study may help to better assess the treatment of glaucoma in the future.

As only data are collected in the study, participation is not associated with any medical risks beyond the ones related to your medical care as decided and performed by the doctor.

Where is the study run from?
BELKIN Vision Ltd.

When is the study starting and how long is it expected to run for?
August 2023 to September 2027

Who is funding the study?
Alcon Ltd

Who is the main contact?
BELKIN Vision: registry@belkin-vision.com
Medevis Consulting: clinicals@medevis-consulting.com

Contact information

Type(s)

Public, Scientific

Contact name

Dr Dorit Raz-Prag

Contact details

BELKIN Vision,
13 Gan Raveh Blvd.
Yavne
Israel
8122214
+41 (0) 79 531 5257
registry@belkin-vision.com

Additional identifiers

Integrated Research Application System (IRAS)

337141

Central Portfolio Management System (CPMS)

60903

Study information

Scientific Title

An observational, registry-based study of performance and safety data from participants treated for open angle glaucoma or ocular hypertension with the Eagle device

Acronym

BELKIN-PMCF

Study objectives

To assess the mean change from baseline in intraocular pressure (IOP) within the 4-8 months post-treatment interval following the direct selective laser trabeculoplasty treatment.

Ethics approval required

Ethics approval required

Ethics approval(s)

1. approved 22/05/2024, West Midlands – Edgbaston (2 Redman Place, Stratford, E20 1JQ, United Kingdom; +44 (0)207 104 8155, (0)207 104 8357; edgbaston.rec@hra.nhs.uk), ref: None provided
2. approved 27/02/2024, Ethik-Kommission Westfalen-Lippe (Gartenstraße 210–214, Münster, 48147, Germany; +49 (0)251 929-2460; ethik-kommission@aekwl.de), ref: 2024-040-f-S
3. approved 27/05/2024, Ethisch Comité UZA/UAntwerpen (Drie Eikenstraat 655, Edegem, 2650, Belgium; +32 (0)3 821 38 97; ethisch.comite@uza.be), ref: 6219
4. approved 13/08/2025, EC Hospital Clinico San Carlos (Puerta G - 4a Norte, Madrid, 28040, Spain; +34 (0)917044158; ceic.hcsc@salud.madrid.org), ref: 25/581-IC_P (O)
5. approved 31/10/2024, Helsinki Committee (Arison Medical Tower, Floor 33 , 6 Weizmann Street, Tel-Aviv, 64239, Israel; +972 (0)36973814; mop@tlvmc.gov.il), ref: 0100-24-SZMC
6. approved 21/11/2024, Segreteria Tecnico-Scientifica del Comitato Etico Territoriale Campania 2 (Luigi Vanvitelli, Edificio 15/A, V Piano, Via Sergio Pansini, 5, Naples, 80131, Italy; +39 (0)81 5664008/09/10; Comitato.Etico@policliniconapoli.it), ref: BELKIN-PMCF

Study design

Observational

Primary study design

Observational

Study type(s)

Safety, Efficacy

Health condition(s) or problem(s) studied

Glaucoma and ocular hypertension

Interventions

The purpose of this registry is to evaluate the effectiveness and safety of the Eagle device when used within its designated use as outlined by the CE-marking and in adherence to standard care protocols. The information gathered will aid in the proactive monitoring of device performance and safety, aligning with the post-market surveillance requirements outlined in Regulation (EU) 2017/745.

Initially, participants will undergo direct selective laser trabeculoplasty (DSLT) using the Eagle device to manage the elevated eye pressure associated with their glaucoma. This study seeks to analyze the average change in intraocular pressure (IOP) from baseline for 4-8 months post-treatment.

The primary outcome assesses changes in IOP over time and the secondary outcomes will investigate the performance and safety of Eagle device in adult participants treated for open-angle glaucoma or ocular hypertension.

This is an observational study and the data collection plan is not compulsory but offers a template for data collection depending on the standard of care in force at the site.

The registry data will be collected at the three predefined post-treatment intervals of 0-4 months, 4-8 months and 8-12 months.

When multiple visits occur within a single registry interval, then the latest available assessment taken within the interval is the one collected as part of the registry.

Participants may not have data at all 3 post-treatment intervals.

The following key data points are to be collected for both eyes, if performed by the investigators as part of the standard of care and where applicable the case report form will collect the information on right, left or both eyes, where applicable:

Data collection before DSLT performed with the Eagle device:

- Participant demographics (age and gender)
- Ethnic group of the participant
- Type of glaucoma
- Angle pigmentation
- Number and names of ocular medications at 1st treatment
- Previous procedures

Data collection on the day of standard of care DSLT performed with the Eagle device:

- Date of procedure, baseline IOP, baseline BCDVA, baseline refraction
- Treatment area (180° or 360)
- Laser energy used for treatment on each participant's eye
- Physician's assessment on the usability
- Participant satisfaction after treatment

Data collection after DSLT performed with the Eagle device:

- IOP at each follow-up interval
- Refraction at each follow-up interval (Optional)
- Post-treatment surgical intervention
- BCDVA at each follow-up interval
- Name of ocular medications, if any, at follow-up intervals
- Rates of Adverse Device Effects

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Eagle®

Primary outcome(s)

Intraocular pressure (IOP) measured using data collected in medical records at the standard of care timepoint within the 4-8 months post-treatment interval following the direct selective laser trabeculoplasty treatment

Key secondary outcome(s)

1. Performance of the device measured using data collected in patient medical records associated with the evaluation of IOP, potential post-treatment surgical intervention, retreatments with the Eagle device and ocular medication of the participant after treatment at the study end
2. Device safety measured using data collected in patient medical records associated with the rate of adverse device effects and device deficiencies at the study end
3. The usability for the practitioner measured using a bespoke questionnaire at the direct selective laser trabeculoplasty (DSLTL) procedure visit
4. Patient experience measured using a bespoke questionnaire at the DSLTL procedure visit

Completion date

30/09/2027

Eligibility**Key inclusion criteria**

1. Adult participants who underwent treatment with the Eagle device for treatment of Open Angle Glaucoma including exfoliative or pigmentary glaucoma or ocular hypertension as per the approved indication.
2. Participants with expected post-operative follow-up data of at least six (6) months

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 years

Upper age limit

110 years

Sex

All

Total final enrolment

355

Key exclusion criteria

Records of participants with any of the following conditions at the date of the treatment with the Eagle device, will not be included in the data collection:

1. Participants who are unable to fixate their head and/or eyes, such as participants suffering from nystagmus, tremors or similar conditions.
2. Participants with congenital glaucoma or active anterior segment inflammations.
3. Participants with any condition that obscures the limbus, such as melanosis affecting the limbus, severe arcus senilis affecting the limbus, pterygium affecting the limbus or any other such conditions.
4. Participants with any condition that causes poor visualization of the limbus that prevents the Eagle device's treatment target identification.

Date of first enrolment

01/05/2024

Date of final enrolment

27/02/2026

Locations

Countries of recruitment

United Kingdom

England

Scotland

Belgium

Germany

Israel

Italy

Spain

Study participating centre

Highlands Treatment Centre

Campus

Inversness

Scotland

IV2 5NA

Study participating centre

Moorfields Eye Hospital (City Road Campus)

162 City Road

London
England
EC1V 2PD

Study participating centre
Leicester Royal Infirmary Laboratory
Leicester Royal Infirmary
Infirmary Square
Leicester
England
LE1 5WW

Study participating centre
Ayrshire Eye Clinic
3, Broomfield Road
Ayr
Scotland
KA7 2SP

Study participating centre
Shaare Zedek Medical Center
Shmuel (Hans) Beyth St 12
Jerusalem
Israel
9103102

Study participating centre
Vision Medica
Via Salaria, 400
Rome RM
Italy
00199

Study participating centre
Università della Campania, Luigi Vanvitelli
Viale Abramo Lincoln, 5
Caserta CE
Italy
81100

Study participating centre
Oogcentrum Medipolis
Boomsesteenweg 223
Wilrijk
Belgium
2610

Study participating centre
University Eye Clinic
In der Schornau 23-25
Bochum
Germany
44892

Study participating centre
Oftalvist Juan Bravo 1
Calle Juan Bravo 1
Madrid
Spain
28006

Study participating centre
Clinica Rementeria
c/Almagro 36, Entreplanta derecha
Madrid
Spain
28010

Study participating centre
Oftalvist Alicante
C/ Ángel Lozano, 11
Alicante
Spain
03001

Sponsor information

Organisation
BELKIN Vision Ltd.

Funder(s)

Funder type

Industry

Funder Name

Alcon

Alternative Name(s)

Funding Body Type

Government organisation

Funding Body Subtype

For-profit companies (industry)

Location

United States of America

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Study website	Study website	11/11/2025	11/11/2025	No	Yes